Join Foghorn Therapeutics for a virtual investor event to review updates for FHD-909, a potential first-in-class selective SMARCA2 inhibitor, including new preclinical combination data being presented at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting. FHD-909 is in ongoing Phase 1 evaluation in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population in collaboration with Lilly.

The Company will also review new preclinical data from their Selective CBP degrader program in combination with chemotherapy and targeted agents and their Selective EP300 degrader programs in hematological malignancies. An overview of the Selective ARID1B degrader program, a synthetic lethal target implicated in up to 5% of all solid tumors, will also be provided.

A live question and answer session will follow the formal presentations.